Multiple Sclerosis (MS): Difference between revisions
No edit summary |
No edit summary |
||
| Line 9: | Line 9: | ||
Multiple Sclerosis (MS) is an autoimmune disorder in which the body's immune cells attack the central nervous system (CNS), affecting the brain, spinal cord and optic nerve<ref name="Pubmed" />. MS is characterized by inflammation, demyelination and gliosis<ref name="Rehab PT" />. An inflammatory response occurs when the body's immune cells attack the CNS, which leads to an increase in pressure and therefore disrupting the nerve conductivity. Demyelination is a process where a nerves protective covering, known as myelin, is damaged due to the autoimmune response leading to decreased nerve conduction velocity and early fatigue of the nerve. Gliosis occurs when demyelinated areas become fibrotic, which causes proliferation of neuroglial tissue in the CNS and leads to scarring of the tissue<ref name="Rehab PT">O'Sullivan S, Schmitz T, Fulk G: Physical Rehabilitation. 6th edition. Philadelphia, PA. F.A. Davis Company; 2014.</ref>. | Multiple Sclerosis (MS) is an autoimmune disorder in which the body's immune cells attack the central nervous system (CNS), affecting the brain, spinal cord and optic nerve<ref name="Pubmed" />. MS is characterized by inflammation, demyelination and gliosis<ref name="Rehab PT" />. An inflammatory response occurs when the body's immune cells attack the CNS, which leads to an increase in pressure and therefore disrupting the nerve conductivity. Demyelination is a process where a nerves protective covering, known as myelin, is damaged due to the autoimmune response leading to decreased nerve conduction velocity and early fatigue of the nerve. Gliosis occurs when demyelinated areas become fibrotic, which causes proliferation of neuroglial tissue in the CNS and leads to scarring of the tissue<ref name="Rehab PT">O'Sullivan S, Schmitz T, Fulk G: Physical Rehabilitation. 6th edition. Philadelphia, PA. F.A. Davis Company; 2014.</ref>. | ||
The course that MS can take will be different from one person to another as well as unpredictable. The disease can be divided into four clinical subytpes, which describe how the disease will progress as well as the corresponding characteristics that become evident for each subtype. Relapsing-remitting MS (RRMS) is the most commone subtype, affecting 85% of people with MS and is characterized by short attacks to the CNS followed by complete or partial return to normal functioning<ref name="Rehab PT" />. Secondary-progressive MS (SPMS) is a subgroup that begins as a relapsing-remitting course accompanied by a steady decline in function and is often developed by patient. Primary-Progressive MS (PPMS) is a progression of the disease where a steady decline in function experienced from the onset of the disease. Progressive-Relapsing MS (PRMS) is similar to PPMS but has the additional characteristic of acute attacks. | The course that MS can take will be different from one person to another as well as unpredictable. The disease can be divided into four clinical subytpes, which describe how the disease will progress as well as the corresponding characteristics that become evident for each subtype. Relapsing-remitting MS (RRMS) is the most commone subtype, affecting 85% of people with MS and is characterized by short attacks to the CNS followed by complete or partial return to normal functioning<ref name="Rehab PT" />. Secondary-progressive MS (SPMS) is a subgroup that begins as a relapsing-remitting course accompanied by a steady decline in function and is often developed by patient. Primary-Progressive MS (PPMS) is a progression of the disease where a steady decline in function experienced from the onset of the disease. Progressive-Relapsing MS (PRMS) is similar to PPMS but has the additional characteristic of acute attacks.<br> | ||
== Prevalence == | == Prevalence == | ||
It is estimated that in the United States there are 400,000 people being affected by MS and 2.1 million people globally<ref name="Rehab PT" />. Females are 2 to 3 times more likely to have MS than males, which may indicate hormones play a role in acquiring the disease<ref name="NMSS" />. The prevalence of MS has increased within the last 5 decades with the increase primarily being due to females<ref name="Rehab PT" />. MS rarely occurs in children as well as adults over the age of 50 and will most commonly present between the ages of 20-40 years<ref name="Rehab PT" />. The risk of being diagnosed with MS is increased in a person who has a sibling with MS by 3%, a fraternal twin by 5% and an identical twin by 25%<ref name="Rehab PT" />. | It is estimated that in the United States there are 400,000 people being affected by MS and 2.1 million people globally<ref name="Rehab PT" />. Females are 2 to 3 times more likely to have MS than males, which may indicate hormones play a role in acquiring the disease<ref name="NMSS" />. The prevalence of MS has increased within the last 5 decades with the increase primarily being due to females<ref name="Rehab PT" />. MS rarely occurs in children as well as adults over the age of 50 and will most commonly present between the ages of 20-40 years<ref name="Rehab PT" />. The risk of being diagnosed with MS is increased in a person who has a sibling with MS by 3%, a fraternal twin by 5% and an identical twin by 25%<ref name="Rehab PT" />. | ||
<br> MS can occur in many ethnics groups, with the most common populations being Caucasians with an ancestry from nothorn Europe, followed by African-Americans, latinos/hispanics and asians<ref name="NMSS" />. It is rarely seen in ethnic populations such as, Australian Aborigines, New-Zealanders, Yakutes, Inuit, Hungarian Romani and Norwegian Lapps<ref name="NMSS" />. There have been studies that show the prevalence of MS is higher in some geographical locations than in others, such as northern United States, norther Europe, southern Canada, New Zealand, Southern Australia and Scandinavian countries. Regions with a lower prevalence of MS tend to be closer to the equator, such as Asia, Africa, and South America<ref name="Rehab PT" />. | <br> MS can occur in many ethnics groups, with the most common populations being Caucasians with an ancestry from nothorn Europe, followed by African-Americans, latinos/hispanics and asians<ref name="NMSS" />. It is rarely seen in ethnic populations such as, Australian Aborigines, New-Zealanders, Yakutes, Inuit, Hungarian Romani and Norwegian Lapps<ref name="NMSS" />. There have been studies that show the prevalence of MS is higher in some geographical locations than in others, such as northern United States, norther Europe, southern Canada, New Zealand, Southern Australia and Scandinavian countries. Regions with a lower prevalence of MS tend to be closer to the equator, such as Asia, Africa, and South America<ref name="Rehab PT" />. | ||
== Characteristics/Clinical Presentation == | == Characteristics/Clinical Presentation == | ||
Revision as of 03:10, 21 March 2014
Original Editors -Sarah Demarest & Beth Niehbur from Bellarmine University's Pathophysiology of Complex Patient Problems project.
Top Contributors - Elizabeth Niebuhr, Vidya Acharya, Sarah Demarest, Laura Ritchie, Nikhil Benhur Abburi, Garima Gedamkar, Kim Jackson, Bram Van Laer, Lucinda hampton, Admin, Eta Frida, Rachael Lowe, Magdalena Hytros, WikiSysop, Naomi O'Reilly, Venus Pagare, Sheik Abdul Khadir, 127.0.0.1, Elaine Lonnemann, Wendy Walker, Evan Thomas, Memoona Awan, Elien Lebuf, Tarina van der Stockt, Rucha Gadgil, Jaroslaw Pospiech, Jess Bell and Rishika Babburu </div>
Definition/Description[edit | edit source]
Multiple Sclerosis (MS) is an autoimmune disorder in which the body's immune cells attack the central nervous system (CNS), affecting the brain, spinal cord and optic nerve[1]. MS is characterized by inflammation, demyelination and gliosis[2]. An inflammatory response occurs when the body's immune cells attack the CNS, which leads to an increase in pressure and therefore disrupting the nerve conductivity. Demyelination is a process where a nerves protective covering, known as myelin, is damaged due to the autoimmune response leading to decreased nerve conduction velocity and early fatigue of the nerve. Gliosis occurs when demyelinated areas become fibrotic, which causes proliferation of neuroglial tissue in the CNS and leads to scarring of the tissue[2].
The course that MS can take will be different from one person to another as well as unpredictable. The disease can be divided into four clinical subytpes, which describe how the disease will progress as well as the corresponding characteristics that become evident for each subtype. Relapsing-remitting MS (RRMS) is the most commone subtype, affecting 85% of people with MS and is characterized by short attacks to the CNS followed by complete or partial return to normal functioning[2]. Secondary-progressive MS (SPMS) is a subgroup that begins as a relapsing-remitting course accompanied by a steady decline in function and is often developed by patient. Primary-Progressive MS (PPMS) is a progression of the disease where a steady decline in function experienced from the onset of the disease. Progressive-Relapsing MS (PRMS) is similar to PPMS but has the additional characteristic of acute attacks.
Prevalence[edit | edit source]
It is estimated that in the United States there are 400,000 people being affected by MS and 2.1 million people globally[2]. Females are 2 to 3 times more likely to have MS than males, which may indicate hormones play a role in acquiring the disease[3]. The prevalence of MS has increased within the last 5 decades with the increase primarily being due to females[2]. MS rarely occurs in children as well as adults over the age of 50 and will most commonly present between the ages of 20-40 years[2]. The risk of being diagnosed with MS is increased in a person who has a sibling with MS by 3%, a fraternal twin by 5% and an identical twin by 25%[2].
MS can occur in many ethnics groups, with the most common populations being Caucasians with an ancestry from nothorn Europe, followed by African-Americans, latinos/hispanics and asians[3]. It is rarely seen in ethnic populations such as, Australian Aborigines, New-Zealanders, Yakutes, Inuit, Hungarian Romani and Norwegian Lapps[3]. There have been studies that show the prevalence of MS is higher in some geographical locations than in others, such as northern United States, norther Europe, southern Canada, New Zealand, Southern Australia and Scandinavian countries. Regions with a lower prevalence of MS tend to be closer to the equator, such as Asia, Africa, and South America[2].
Characteristics/Clinical Presentation[edit | edit source]
add text here
Associated Co-morbidities[edit | edit source]
add text here
Medications[edit | edit source]
add text here
Diagnostic Tests/Lab Tests/Lab Values[edit | edit source]
add text here
Etiology/Causes[edit | edit source]
add text here
Systemic Involvement[edit | edit source]
add text here
Medical Management (current best evidence)[edit | edit source]
add text here
Physical Therapy Management (current best evidence)[edit | edit source]
add text here
Alternative/Holistic Management (current best evidence)[edit | edit source]
add text here
Differential Diagnosis[edit | edit source]
add text here
Case Reports/ Case Studies[edit | edit source]
add links to case studies here (case studies should be added on new pages using the case study template)
Resources
[edit | edit source]
add appropriate resources here
Recent Related Research (from Pubmed)[edit | edit source]
see tutorial on Adding PubMed Feed
Extension:RSS -- Error: Not a valid URL: addfeedhere|charset=UTF-8|short|max=10
References[edit | edit source]
- ↑ 1.0 1.1 U.S National Library of Medicine. PubMed Health. Multiple Sclerosis. September 25, 2013. Available at:http: //www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001747/,Accessed March 19, 2014.
- ↑ 2.0 2.1 2.2 2.3 2.4 2.5 2.6 2.7 O'Sullivan S, Schmitz T, Fulk G: Physical Rehabilitation. 6th edition. Philadelphia, PA. F.A. Davis Company; 2014.
- ↑ 3.0 3.1 3.2 Cite error: Invalid
<ref>tag; no text was provided for refs namedNMSS
see adding references tutorial.
